Published • loading... • Updated
Acadia’s Alzheimer’s Psychosis Drug Misses Main Goal of Mid-Stage Study
The 60 mg dose showed a statistical benefit on a secondary measure, and Acadia will continue Phase 3 studies while dropping the 30 mg arm.
- On Thursday, Acadia Pharmaceuticals announced its experimental drug remlifanserin missed the primary goal of a mid-stage study testing whether it could reduce hallucinations and delusions in Alzheimer's disease psychosis patients, sending shares down about 11%.
- Approximately 30% of patients with Alzheimer's disease experience psychosis involving frequent hallucinations and delusions; these symptoms increase caregiver burden and nursing home placement, yet no therapies are currently approved specifically for this condition.
- While the 60-milligram dose showed greater improvement than placebo, it fell short of the primary goal; however, the dose achieved statistical significance on a key secondary endpoint measuring overall symptom severity, with safety profiles remaining similar to placebo.
- Acadia will continue enrolling patients in two ongoing late-stage studies while removing the 30-milligram treatment arm from the program; BMO Capital Markets analyst Evan Seigerman noted the secondary success suggests a potential path forward.
- Despite the missed primary goal, the company still expects remlifanserin to generate about $4 billion in peak sales potential; Acadia plans to present detailed results at the Clinical Trials on Alzheimer's Disease conference on November 16.
Insights by Ground AI
12 Articles
12 Articles
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study
·London, United Kingdom
Read Full Article
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis, or ADP. The company said the 60 mg once-daily dose narrowly missed statist
·Sioux Falls, United States
Read Full Article
Financial PostReposted by 
India Shorts
India ShortsAcadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis (ADP)
— Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated…
·Toronto, Canada
Read Full Article
Coverage Details
Total News Sources12
Leaning Left0Leaning Right4Center5Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
C 56%
R 44%
Factuality
To view factuality data please Upgrade to Premium
